marketing
PORTAL
LOGIN
Don't Have An Account?
REGISTER NOW
Menu

Breakthrough Gene Technology Attracts Investors Amid Patent Dispute

Last month, Bayer AG opened the doors on a $335 million joint venture with Crispr Therapeutics to develop therapies using a new gene-editing tool. Later this year, rival Editas Medicine Inc. will move into larger digs as it, too, races ahead with a $200 million-plus effort to leverage the gene-editing tool into new drugs. The flurry belies the fact that the companies don’t actually know yet who owns the intellectual-property rights to the technology.http://www.wsj.com/articles/breakthrough-gene-technology-attracts-investors-amid-patent-dispute-1474567512

Share this Information

Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn

have a question?

Fill out this form and let us know.

CONTACT US

Tel: 208-424-2249

9AM - 5PM Monday-Friday

PO BOX 99
Meridian, ID 83680

Copyright © 2019 Strategic Risk Alternatives. All Rights Reserved.